160 related articles for article (PubMed ID: 24564171)
1. A gene signature based method for identifying subtypes and subtype-specific drivers in cancer with an application to medulloblastoma.
Chen P; Fan Y; Man TK; Hung YS; Lau CC; Wong ST
BMC Bioinformatics; 2013; 14 Suppl 18(Suppl 18):S1. PubMed ID: 24564171
[TBL] [Abstract][Full Text] [Related]
2. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
3. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
[TBL] [Abstract][Full Text] [Related]
4. A transcriptome-based classifier to determine molecular subtypes in medulloblastoma.
Rathi KS; Arif S; Koptyra M; Naqvi AS; Taylor DM; Storm PB; Resnick AC; Rokita JL; Raman P
PLoS Comput Biol; 2020 Oct; 16(10):e1008263. PubMed ID: 33119584
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA profiling of pediatric Medulloblastoma.
Kesherwani V; Shukla M; Coulter DW; Sharp JG; Joshi SS; Chaturvedi NK
BMC Med Genomics; 2020 Jun; 13(1):87. PubMed ID: 32591022
[TBL] [Abstract][Full Text] [Related]
6. Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
Richardson S; Hill RM; Kui C; Lindsey JC; Grabovksa Y; Keeling C; Pease L; Bashton M; Crosier S; Vinci M; André N; Figarella-Branger D; Hansford JR; Lastowska M; Zakrzewski K; Jorgensen M; Pickles JC; Taylor MD; Pfister SM; Wharton SB; Pizer B; Michalski A; Joshi A; Jacques TS; Hicks D; Schwalbe EC; Williamson D; Ramaswamy V; Bailey S; Clifford SC
Neuro Oncol; 2022 Jan; 24(1):153-165. PubMed ID: 34272868
[TBL] [Abstract][Full Text] [Related]
7. The molecular classification of medulloblastoma: driving the next generation clinical trials.
Leary SE; Olson JM
Curr Opin Pediatr; 2012 Feb; 24(1):33-9. PubMed ID: 22189395
[TBL] [Abstract][Full Text] [Related]
8. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
9. Identification of cell surface targets through meta-analysis of microarray data.
Haeberle H; Dudley JT; Liu JT; Butte AJ; Contag CH
Neoplasia; 2012 Jul; 14(7):666-9. PubMed ID: 22904683
[TBL] [Abstract][Full Text] [Related]
10. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
11. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.
Schwede M; Spentzos D; Bentink S; Hofmann O; Haibe-Kains B; Harrington D; Quackenbush J; Culhane AC
PLoS One; 2013; 8(3):e57799. PubMed ID: 23536770
[TBL] [Abstract][Full Text] [Related]
12. Personalized diagnosis of medulloblastoma subtypes across patients and model systems.
Gendoo DM; Smirnov P; Lupien M; Haibe-Kains B
Genomics; 2015 Aug; 106(2):96-106. PubMed ID: 25979459
[TBL] [Abstract][Full Text] [Related]
13. TuBA: Tunable biclustering algorithm reveals clinically relevant tumor transcriptional profiles in breast cancer.
Singh A; Bhanot G; Khiabanian H
Gigascience; 2019 Jun; 8(6):. PubMed ID: 31216036
[TBL] [Abstract][Full Text] [Related]
14. Spectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypes.
Shi M; Xu G
Sci Rep; 2017 Jul; 7(1):4896. PubMed ID: 28687729
[TBL] [Abstract][Full Text] [Related]
15. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes.
Lu X; Li X; Liu P; Qian X; Miao Q; Peng S
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma comprises four distinct molecular variants.
Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
[TBL] [Abstract][Full Text] [Related]
18. Integrated genomics has identified a new AT/RT-like yet INI1-positive brain tumor subtype among primary pediatric embryonal tumors.
Ho DM; Shih CC; Liang ML; Tsai CY; Hsieh TH; Tsai CH; Lin SC; Chang TY; Chao ME; Wang HW; Wong TT
BMC Med Genomics; 2015 Jun; 8():32. PubMed ID: 26109171
[TBL] [Abstract][Full Text] [Related]
19. SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis.
Li YX; Yu ZW; Jiang T; Shao LW; Liu Y; Li N; Wu YF; Zheng C; Wu XY; Zhang M; Zheng DF; Qi XL; Ding M; Zhang J; Chang Q
Cancer Sci; 2018 Apr; 109(4):1263-1275. PubMed ID: 29369502
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
